Mankind Pharma, a prominent player in the Indian pharmaceutical industry, is headquartered in New Delhi, India. Founded in 1991, the company has established itself as a leader in the development, manufacturing, and marketing of a diverse range of pharmaceutical products, including prescription medications, over-the-counter drugs, and consumer healthcare items. With a strong focus on quality and innovation, Mankind Pharma has achieved significant milestones, including rapid expansion across major operational regions in India and beyond. The company is renowned for its unique formulations and commitment to affordable healthcare, positioning itself as a trusted name among healthcare professionals and consumers alike. Notable achievements include a robust market presence and recognition for its contributions to the pharmaceutical sector, making Mankind Pharma a key player in enhancing health outcomes across the region.
How does Mankind Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Mankind Pharma's score of 27 is lower than 55% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2024, Mankind Pharma reported total carbon emissions of approximately 23,166,000 kg CO2e, comprising 5,831,000 kg CO2e from Scope 1 and 17,335,000 kg CO2e from Scope 2 emissions. Notably, the company has not disclosed any Scope 3 emissions data. This represents a significant reduction from the previous year's total emissions of approximately 14,519,000 kg CO2e, indicating a proactive approach to managing their carbon footprint. Mankind Pharma's emissions data is not cascaded from any parent organization, and they have not set specific reduction targets or climate pledges as per the available information. The company continues to focus on improving its operational efficiency and reducing emissions intensity, as evidenced by their reported emission intensity metrics. Overall, Mankind Pharma is committed to addressing its carbon emissions, although further details on specific reduction initiatives or targets are currently unavailable.
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | 2024 | |
|---|---|---|---|
| Scope 1 | 15,753,000 | 00,000,000 | 0,000,000 |
| Scope 2 | 28,074,000 | - | 00,000,000 |
| Scope 3 | 168,000 | - | - |
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Mankind Pharma has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.

